Cargando…

An In Vivo Inflammatory Loop Potentiates KRAS Blockade

KRAS (KRAS proto-oncogene, GTPase) inhibitors perform less well than other targeted drugs in vitro and fail clinical trials. To investigate a possible reason for this, we treated human and murine tumor cells with KRAS inhibitors deltarasin (targeting phosphodiesterase-δ), cysmethynil (targeting isop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arendt, Kristina A. M., Ntaliarda, Giannoula, Armenis, Vasileios, Kati, Danai, Henning, Christin, Giotopoulou, Georgia A., Pepe, Mario A. A., Klotz, Laura V., Lamort, Anne-Sophie, Hatz, Rudolf A., Kobold, Sebastian, Schamberger, Andrea C., Stathopoulos, Georgios T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945202/ https://www.ncbi.nlm.nih.gov/pubmed/35327394 http://dx.doi.org/10.3390/biomedicines10030592

Ejemplares similares

Interleukin-1β provided by KIT-competent mast cells is required for KRAS-mutant lung adenocarcinoma
por: Lilis, Ioannis, et al.
Publicado: (2019)

Non-Oncogene Addiction of KRAS-Mutant Cancers to IL-1β via Versican and Mononuclear IKKβ
por: Spella, Magda, et al.
Publicado: (2023)

NRAS destines tumor cells to the lungs
por: Giannou, Anastasios D, et al.
Publicado: (2017)

KRAS signaling in malignant pleural mesothelioma
por: Marazioti, Antonia, et al.
Publicado: (2021)

Comprehensive clinical profiling of the Gauting locoregional lung adenocarcinoma donors
por: Klotz, Laura V., et al.
Publicado: (2019)

A role for club cells in smoking-associated lung adenocarcinoma
por: Behrend, Sabine J., et al.
Publicado: (2021)

Club cells form lung adenocarcinomas and maintain the alveoli of adult mice
por: Spella, Magda, et al.
Publicado: (2019)

Mutant KRAS promotes malignant pleural effusion formation
por: Αgalioti, Theodora, et al.
Publicado: (2017)

Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion
por: Marazioti, Antonia, et al.
Publicado: (2018)

Osteopontin as a Link between Inflammation and Cancer: The Thorax in the Spotlight
por: Lamort, Anne-Sophie, et al.
Publicado: (2019)

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
por: Tang, Daolin, et al.
Publicado: (2021)

KRAS Pathway Alterations in Malignant Pleural Mesothelioma: An Underestimated Player
por: Trassl, Lilith, et al.
Publicado: (2022)

Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer
por: Wang, Man-Tzu, et al.
Publicado: (2019)

Wnt1 silences chemokine genes in dendritic cells and induces adaptive immune resistance in lung adenocarcinoma
por: Kerdidani, Dimitra, et al.
Publicado: (2019)

Ferrous iron–activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors
por: Jiang, Honglin, et al.
Publicado: (2022)

Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy
por: Kobold, Sebastian, et al.
Publicado: (2018)

Caspase-11 and AIM2 inflammasome are involved in smoking-induced COPD and lung adenocarcinoma
por: Colarusso, Chiara, et al.
Publicado: (2021)

Heterogeneity of KRAS Mutation Status in Rectal Cancer
por: Jo, Peter, et al.
Publicado: (2016)

Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells
por: Cheon, Seul‐Ki, et al.
Publicado: (2018)

Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy
por: Song, Xinxin, et al.
Publicado: (2022)

Reprogramming of tumor-associated macrophages by targeting β-catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer
por: Sarode, Poonam, et al.
Publicado: (2020)

KRAS: Druggable at Last
por: Herzberg, Benjamin O, et al.
Publicado: (2023)

Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer
por: Ntavatzikos, Anastasios, et al.
Publicado: (2017)

Propofol/Fentanyl/Rocuronium or Sevoflurane Inhalational Induction for Intubation?
por: Mitos, Giakoumis, et al.
Publicado: (2021)

Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer
por: Konen, Jessica M., et al.
Publicado: (2019)

Reverse engineering a hierarchical regulatory network downstream of oncogenic KRAS
por: Stelniec-Klotz, Iwona, et al.
Publicado: (2012)

Impacts of Mutations in the P-Loop on Conformational Alterations of KRAS Investigated with Gaussian Accelerated Molecular Dynamics Simulations
por: Shi, Shuhua, et al.
Publicado: (2023)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
por: Adachi, Yuta, et al.
Publicado: (2021)

Detection and quantification of epithelial progenitor cell populations in human healthy and IPF lungs
por: Smirnova, N. F., et al.
Publicado: (2016)

Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome
por: Lemstrova, Radmila, et al.
Publicado: (2017)

Maximal androgen blockade for the treatment of metastatic prostate cancer—a systematic review
por: Lukka, H., et al.
Publicado: (2006)

Chemokine blockade
por: Wells, William A.
Publicado: (2007)

Novel Methodology for Rapid Detection of KRAS Mutation Using PNA-LNA Mediated Loop-Mediated Isothermal Amplification
por: Itonaga, Masahiro, et al.
Publicado: (2016)

Oncogenic KRAS signalling in pancreatic cancer
por: Eser, S, et al.
Publicado: (2014)

An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer
por: von Karstedt, Silvia, et al.
Publicado: (2020)

KRAS(G12C) Can Either Promote or Impair Cap-Dependent Translation in Two Different Lung Adenocarcinoma Cell Lines
por: Kyriakopoulos, George, et al.
Publicado: (2021)

Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade
por: Umelo, Ijeoma Adaku, et al.
Publicado: (2015)

IL-17C-mediated innate inflammation decreases the response to PD-1 blockade in a model of Kras-driven lung cancer
por: Ritzmann, Felix, et al.
Publicado: (2019)

Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies
por: Kuracha, Murali R., et al.
Publicado: (2017)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ve40tefnaovciot7kpcg8so53b